Terns Pharmaceutical
PrivateLast Round
Follow-on Offering
Dec 11, 2025
Est. Valuation
$430M
Total Funding Raised
$1.12B
Company Overview
Terns Pharmaceuticals (NAS: TERN) is a biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Terns Pharmaceutical Comparables
Compare Terns Pharmaceutical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Viking Therapeutics, Inc. | 82% | |
| Enliven Therapeutics | 82% | |
| Eccogene | 81% |
For institutional investors. Book with your work email.
Terns Pharmaceutical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Dec 11, 2025 | ||||
| Follow-on Offering | Sep 12, 2024 | ||||
| IPO | Feb 10, 2021 | ||||
| Series C | Jan 5, 2021 | ||||
| Series B | Oct 30, 2018 | ||||
Series A | Apr 4, 2018 |
For institutional investors. Book with your work email.
Terns Pharmaceutical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | Follow-on Offering |
| Deerfield Management | Series C |
| Suvretta Capital Management | Series C |
| OrbiMed | Series C, Series B |
| TD Cowen | Follow-on Offering |
| UBS Investment Bank | Follow-on Offering |
| Lilly Asia Ventures | Series B, Series C, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2024
$173M round led by Jefferies and TD Cowen.
For institutional investors. Book with your work email.
Terns Pharmaceutical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Terns Pharmaceutical's valuation, stock price, and market status.
Is Terns Pharmaceutical a public or private company?
Terns Pharmaceutical is a private company.
What is the current stock price of Terns Pharmaceutical?
Terns Pharmaceutical is a private company, so its shares have no public market price. Caplight tracks Terns Pharmaceutical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Terns Pharmaceutical worth (valuation)?
Terns Pharmaceutical's valuation is estimated at $430.0M based on funding round data.
Can I buy Terns Pharmaceutical stock?
Terns Pharmaceutical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Terns Pharmaceutical's last funding round?
Terns Pharmaceutical's most recent funding round was Follow-on Offering on December 11, 2025.
Who are the main investors in Terns Pharmaceutical?
Key investors in Terns Pharmaceutical include Jefferies, Deerfield Management, OrbiMed, TD Cowen, Lilly Asia Ventures.
Will Terns Pharmaceutical IPO soon?
No public IPO plans have been announced for Terns Pharmaceutical.
How can I track Terns Pharmaceutical secondary market activity?
Caplight tracks bids, offers, and trades in Terns Pharmaceutical's shares on secondary markets.